Treatment with minocycline after disease onset alters astrocyte reactivity and increases microgliosis in SOD1 mutant mice

[1]  M. Cohen-Salmon,et al.  Cannabinoids prevent the opposite regulation of astroglial connexin43 hemichannels and gap junction channels induced by pro‐inflammatory treatments , 2009, Journal of neurochemistry.

[2]  A Florence Keller,et al.  Live imaging of amyotrophic lateral sclerosis pathogenesis: Disease onset is characterized by marked induction of GFAP in Schwann cells , 2009, Glia.

[3]  W. Robberecht,et al.  Ablation of Proliferating Microglia Does Not Affect Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis Caused by Mutant Superoxide Dismutase , 2008, The Journal of Neuroscience.

[4]  J. Julien,et al.  Requirement of Myeloid Cells for Axon Regeneration , 2008, The Journal of Neuroscience.

[5]  T. Kielian.  Glial connexins and gap junctions in CNS inflammation and disease , 2008, Journal of neurochemistry.

[6]  M. Sofroniew,et al.  Selective ablation of proliferating astrocytes does not affect disease outcome in either acute or chronic models of motor neuron degeneration , 2008, Experimental Neurology.

[7]  Y. Weng,et al.  Live Imaging of Neuroinflammation Reveals Sex and Estrogen Effects on Astrocyte Response to Ischemic Injury , 2008, Stroke.

[8]  D. Gutmann,et al.  Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis , 2008, Nature Neuroscience.

[9]  M. Carrì.  Minocycline for patients with ALS , 2008, The Lancet Neurology.

[10]  V. Meininger,et al.  Minocycline for patients with ALS , 2008, The Lancet Neurology.

[11]  H. Mitsumoto,et al.  Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial , 2007, The Lancet Neurology.

[12]  I. Torres-Aleman,et al.  Calcineurin in Reactive Astrocytes Plays a Key Role in the Interplay between Proinflammatory and Anti-Inflammatory Signals , 2007, The Journal of Neuroscience.

[13]  D. Maysinger,et al.  Real-time imaging of astrocyte response to quantum dots: in vivo screening model system for biocompatibility of nanoparticles. , 2007, Nano letters.

[14]  Hynek Wichterle,et al.  Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons , 2007, Nature Neuroscience.

[15]  Kevin Eggan,et al.  Non–cell autonomous effect of glia on motor neurons in an embryonic stem cell–based ALS model , 2007, Nature Neuroscience.

[16]  M. Benatar.  Lost in translation: Treatment trials in the SOD1 mouse and in human ALS , 2007, Neurobiology of Disease.

[17]  G. Gowing,et al.  Selective Ablation of Proliferating Microglial Cells Exacerbates Ischemic Injury in the Brain , 2007, The Journal of Neuroscience.

[18]  Milos Pekny,et al.  Redefining the concept of reactive astrocytes as cells that remain within their unique domains upon reaction to injury , 2006, Proceedings of the National Academy of Sciences.

[19]  J. Julien,et al.  Absence of Tumor Necrosis Factor-α Does Not Affect Motor Neuron Disease Caused by Superoxide Dismutase 1 Mutations , 2006, The Journal of Neuroscience.

[20]  S. Mckercher,et al.  Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis , 2006, Proceedings of the National Academy of Sciences.

[21]  D. Cleveland,et al.  ALS: A Disease of Motor Neurons and Their Nonneuronal Neighbors , 2006, Neuron.

[22]  M. Sofroniew,et al.  Essential protective roles of reactive astrocytes in traumatic brain injury. , 2006, Brain : a journal of neurology.

[23]  G. Kollias,et al.  Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia , 2006, Science.

[24]  B. Rosen,et al.  Role of matrix metalloproteinases in delayed cortical responses after stroke , 2006, Nature Medicine.

[25]  C. Giaume,et al.  Proinflammatory cytokines released from microglia inhibit gap junctions in astrocytes: potentiation by β‐amyloid , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  L. Barbeito,et al.  Fibroblast Growth Factor-1 Induces Heme Oxygenase-1 via Nuclear Factor Erythroid 2-related Factor 2 (Nrf2) in Spinal Cord Astrocytes , 2005, Journal of Biological Chemistry.

[27]  M. Nilsson,et al.  Astrocyte activation and reactive gliosis , 2005, Glia.

[28]  Lingyun Zhu,et al.  Non-invasive imaging of GFAP expression after neuronal damage in mice , 2004, Neuroscience Letters.

[29]  L. Bruijn,et al.  Unraveling the mechanisms involved in motor neuron degeneration in ALS. , 2004, Annual review of neuroscience.

[30]  Taizen Nakase,et al.  Gap junctions and neurological disorders of the central nervous system. , 2004, Biochimica et biophysica acta.

[31]  Ngan B. Doan,et al.  Reactive Astrocytes Protect Tissue and Preserve Function after Spinal Cord Injury , 2004, The Journal of Neuroscience.

[32]  Minh N. H. Nguyen,et al.  Wild-Type Nonneuronal Cells Extend Survival of SOD1 Mutant Motor Neurons in ALS Mice , 2003, Science.

[33]  R. Hurlbert,et al.  Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. , 2003, Brain : a journal of neurology.

[34]  Jean-Pierre Julien,et al.  Efficient three‐drug cocktail for disease induced by mutant superoxide dismutase , 2003, Annals of neurology.

[35]  J. Rothstein,et al.  Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS , 2002, Annals of neurology.

[36]  J. Julien,et al.  Minocycline Slows Disease Progression in a Mouse Model of Amyotrophic Lateral Sclerosis , 2002, Neurobiology of Disease.

[37]  Tony Wyss-Coray,et al.  Inflammation in Neurodegenerative Disease—A Double-Edged Sword , 2002, Neuron.

[38]  W. Robberecht,et al.  Minocycline delays disease onset and mortality in a transgenic model of ALS , 2002, Neuroreport.

[39]  V. Yong,et al.  Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. , 2002, Brain : a journal of neurology.

[40]  Betty Y. S. Kim,et al.  Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice , 2002, Nature.

[41]  Dong-Kug Choi,et al.  Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease , 2002, The Journal of Neuroscience.

[42]  S. Paul,et al.  Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Julien,et al.  Amyotrophic Lateral Sclerosis Unfolding the Toxicity of the Misfolded , 2001, Cell.

[44]  M. Fini,et al.  Role for Matrix Metalloproteinase 9 after Focal Cerebral Ischemia: Effects of Gene Knockout and Enzyme Inhibition with BB-94 , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[45]  Y. Kawaoka,et al.  Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice , 2000, Nature Medicine.

[46]  S. Hersch,et al.  Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease , 2000, Nature Medicine.

[47]  C. Brosnan,et al.  IL-1beta differentially regulates calcium wave propagation between primary human fetal astrocytes via pathways involving P2 receptors and gap junction channels. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[48]  T. Hökfelt,et al.  Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[49]  N. Severs,et al.  CONNEXIN EXPRESSION IN HUNTINGTON'S DISEASED HUMAN BRAIN , 1998, Cell biology international.

[50]  M. Gurney,et al.  Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS , 1998 .

[51]  E. Hertzberg,et al.  Elevated connexin43 immunoreactivity at sites of amyloid plaques in alzheimer's disease , 1996, Brain Research.

[52]  M. Gurney,et al.  Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. , 1994, Science.

[53]  P. Mcgeer,et al.  Reactions of the Immune System in Chronic Degenerative Neurological Diseases , 1991, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[54]  M. Gurney,et al.  Pathogenic mechanisms in familial amyotrophic lateral sclerosis due to mutation of Cu, Zn superoxide dismutase. , 1996, Pathologie-biologie.